UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 22, 2018
CESCA THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
|
||
|
Delaware |
|
333-82900 |
|
94-3018487 |
||
|
|
|
|
|
|
||
|
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
||
|
of Incorporation) |
|
File Number) |
|
Identification No.) |
||
|
|
|
|
||||
|
2711 Citrus Road, Rancho Cordova, California |
|
95742 |
||||
|
|
|
|
||||
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
||||
Registrant’s telephone number, including area code: (949) 753-0624
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition. |
On March 22, 2018, Cesca Therapeutics Inc. issued a press release announcing its results of operations and financial condition for the transition period from July 1, 2017 to December 31, 2017, which is necessary to accommodate the change in the Company’s fiscal year end from June 30 to December 31. The full text of the press release is set forth in Exhibit 99.1 attached to this Current Report on Form 8-K.
This press release includes adjusted EBITDA, which is a financial measure that is not determined in accordance with United States generally accepted accounting principles “U.S. GAAP”. Adjusted EBITDA represents loss from operations excluding amounts for depreciation and amortization, stock-based compensation expense and impairment of intangible asset. Adjusted EBITDA should not be considered in isolation or as a substitute for net loss as a measure of performance. A reconciliation to the comparable GAAP measure is provided in the accompanying financial summaries.
The information contained in this Item 2.02 and in Exhibit 99.1 attached to this Current Report on Form 8-K is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, except as shall be expressly set forth in such a filing.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
Exhibit No. |
Description |
|
|
99.1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CESCA THERAPEUTICS INC. |
||
|
(Registrant) |
||
|
Dated: March 22, 2018 |
/s/ Vivian Liu |
|
|
Vivian Liu, Chief Operating Officer |